Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2024 / Nov / Exposing Aggressive Cancer Traits
Oncology Oncology Technology and innovation

Exposing Aggressive Cancer Traits

Advanced single-cell imaging reveals key cancer-stroma interactions linked to poor survival in head and neck cancer patients

By Jessica Allerton 11/13/2024 News 1 min read

Share

A study published in Cell introduces a multiparameter imaging method that maps how cancer cells interact with surrounding tissue in head and neck squamous cell carcinoma (HNSCC).

Credit: Adobe Stock

Researchers studied tissue samples from 212 HNSCC patients. Using advanced single-cell imaging, they found that a specific type of cancer cell, known as the partial epithelial-mesenchymal transition (pEMT) cell, was tied to aggressive cancer growth. When these pEMT cells were combined with cancer-associated fibroblasts (CAFs), the cancer cells became more invasive. This interaction was driven by specific signaling pathways, including the amphiregulin and epidermal growth factor (AREG/EGF) pathway.

The study also categorized the surrounding tissue (stroma) into three types: immune-enriched, CAF-enriched, and myeloid-rich. Findings showed that patients with CAF-enriched tissue had lower survival rates than those with immune-enriched tissue. Indeed, the combination of pEMT cancer cells and CAF-rich stroma was identified as a strong predictor of poor outcomes.

“Our research utilizes the latest analysis methods in machine learning and spatial biology. We analyze hundreds of patient samples and millions of cells, which is only possible with the help of high-performance computers and artificial intelligence,” research director Sara Wickström explained in a press release. “This study is part of a new revolution in cancer diagnostics. We believe that the technology will significantly improve cancer diagnostics and the accuracy of treatment strategies.”

This research offers a new prognostic tool for identifying HNSCC patients with higher risks of aggressive disease. By examining the stromal composition alongside cancer cell phenotypes, clinicians could better predict patient outcomes and tailor treatments. Moreover, further studies could confirm whether targeting CAF and pEMT interactions can improve therapeutic outcomes for patients with these aggressive tumor profiles​.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.